CN114073731A - A Chinese medicinal composition for treating abdominal pain and diarrhea - Google Patents
A Chinese medicinal composition for treating abdominal pain and diarrhea Download PDFInfo
- Publication number
- CN114073731A CN114073731A CN202010815618.9A CN202010815618A CN114073731A CN 114073731 A CN114073731 A CN 114073731A CN 202010815618 A CN202010815618 A CN 202010815618A CN 114073731 A CN114073731 A CN 114073731A
- Authority
- CN
- China
- Prior art keywords
- diarrhea
- radix
- fructus aurantii
- traditional chinese
- chinese medicine
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 206010012735 Diarrhoea Diseases 0.000 title claims abstract description 44
- 208000004998 Abdominal Pain Diseases 0.000 title claims abstract description 32
- 239000000203 mixture Substances 0.000 title claims abstract description 32
- 239000003814 drug Substances 0.000 claims abstract description 42
- 244000303040 Glycyrrhiza glabra Species 0.000 claims abstract description 12
- 235000006200 Glycyrrhiza glabra Nutrition 0.000 claims abstract description 12
- 241000112528 Ligusticum striatum Species 0.000 claims abstract description 12
- 244000274050 Platycodon grandiflorum Species 0.000 claims abstract description 12
- 235000006753 Platycodon grandiflorum Nutrition 0.000 claims abstract description 12
- 241000951473 Schizonepeta Species 0.000 claims abstract description 12
- LPLVUJXQOOQHMX-QWBHMCJMSA-N glycyrrhizinic acid Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@@H]1C([C@H]2[C@]([C@@H]3[C@@]([C@@]4(CC[C@@]5(C)CC[C@@](C)(C[C@H]5C4=CC3=O)C(O)=O)C)(C)CC2)(C)CC1)(C)C)C(O)=O)[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O LPLVUJXQOOQHMX-QWBHMCJMSA-N 0.000 claims abstract description 12
- 235000011477 liquorice Nutrition 0.000 claims abstract description 12
- 241001180876 Saposhnikovia Species 0.000 claims abstract description 11
- 210000001035 gastrointestinal tract Anatomy 0.000 claims abstract description 7
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 46
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 40
- 238000002156 mixing Methods 0.000 claims description 33
- 238000002360 preparation method Methods 0.000 claims description 30
- 239000008187 granular material Substances 0.000 claims description 21
- 239000000341 volatile oil Substances 0.000 claims description 20
- 201000010099 disease Diseases 0.000 claims description 16
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 16
- 239000006187 pill Substances 0.000 claims description 13
- 241001619461 Poria <basidiomycete fungus> Species 0.000 claims description 12
- 239000012153 distilled water Substances 0.000 claims description 11
- 208000001848 dysentery Diseases 0.000 claims description 10
- 206010012742 Diarrhoea infectious Diseases 0.000 claims description 9
- 239000007788 liquid Substances 0.000 claims description 7
- 238000000034 method Methods 0.000 claims description 7
- 239000000463 material Substances 0.000 claims description 6
- 239000002994 raw material Substances 0.000 claims description 6
- 235000005911 diet Nutrition 0.000 claims description 5
- 239000002775 capsule Substances 0.000 claims description 4
- 241000894006 Bacteria Species 0.000 claims description 3
- 241000700605 Viruses Species 0.000 claims description 3
- 244000045947 parasite Species 0.000 claims description 3
- 241000233866 Fungi Species 0.000 claims description 2
- 208000016222 Pancreatic disease Diseases 0.000 claims description 2
- 230000000378 dietary effect Effects 0.000 claims description 2
- 208000015181 infectious disease Diseases 0.000 claims description 2
- 208000028774 intestinal disease Diseases 0.000 claims description 2
- 239000003826 tablet Substances 0.000 claims description 2
- 208000012895 Gastric disease Diseases 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 208000010643 digestive system disease Diseases 0.000 claims 1
- 208000024557 hepatobiliary disease Diseases 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 12
- 208000002193 Pain Diseases 0.000 abstract description 9
- 244000197580 Poria cocos Species 0.000 abstract description 7
- 235000008599 Poria cocos Nutrition 0.000 abstract description 7
- 230000036407 pain Effects 0.000 abstract description 6
- 239000002858 neurotransmitter agent Substances 0.000 abstract description 5
- 230000035945 sensitivity Effects 0.000 abstract description 4
- 206010061218 Inflammation Diseases 0.000 abstract description 3
- 230000004054 inflammatory process Effects 0.000 abstract description 3
- 239000000126 substance Substances 0.000 abstract description 3
- 206010001497 Agitation Diseases 0.000 abstract description 2
- 229940126680 traditional chinese medicines Drugs 0.000 abstract description 2
- 230000000968 intestinal effect Effects 0.000 abstract 1
- 210000000952 spleen Anatomy 0.000 abstract 1
- 238000005728 strengthening Methods 0.000 abstract 1
- 210000001835 viscera Anatomy 0.000 abstract 1
- 241000700159 Rattus Species 0.000 description 53
- 239000000243 solution Substances 0.000 description 37
- QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 description 20
- 210000003608 fece Anatomy 0.000 description 16
- 238000001914 filtration Methods 0.000 description 15
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 12
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 12
- QDZOEBFLNHCSSF-PFFBOGFISA-N (2S)-2-[[(2R)-2-[[(2S)-1-[(2S)-6-amino-2-[[(2S)-1-[(2R)-2-amino-5-carbamimidamidopentanoyl]pyrrolidine-2-carbonyl]amino]hexanoyl]pyrrolidine-2-carbonyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]-N-[(2R)-1-[[(2S)-1-[[(2R)-1-[[(2S)-1-[[(2S)-1-amino-4-methyl-1-oxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-3-(1H-indol-3-yl)-1-oxopropan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-3-(1H-indol-3-yl)-1-oxopropan-2-yl]pentanediamide Chemical compound C([C@@H](C(=O)N[C@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(N)=O)NC(=O)[C@@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CCCCN)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](N)CCCNC(N)=N)C1=CC=CC=C1 QDZOEBFLNHCSSF-PFFBOGFISA-N 0.000 description 10
- 102400000096 Substance P Human genes 0.000 description 10
- 101800003906 Substance P Proteins 0.000 description 10
- 229940079593 drug Drugs 0.000 description 10
- 238000001035 drying Methods 0.000 description 10
- LVRVABPNVHYXRT-BQWXUCBYSA-N 52906-92-0 Chemical compound C([C@H](N)C(=O)N[C@H](C(=O)N1CCC[C@H]1C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CCC(N)=O)C(O)=O)C(C)C)C1=CC=CC=C1 LVRVABPNVHYXRT-BQWXUCBYSA-N 0.000 description 9
- 102400000921 Gastrin Human genes 0.000 description 9
- 108010052343 Gastrins Proteins 0.000 description 9
- 102400001357 Motilin Human genes 0.000 description 9
- 101800002372 Motilin Proteins 0.000 description 9
- AOXOCDRNSPFDPE-UKEONUMOSA-N chembl413654 Chemical compound C([C@H](C(=O)NCC(=O)N[C@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@H](CCSC)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CC=1C=CC=CC=1)C(N)=O)NC(=O)[C@@H](C)NC(=O)[C@@H](CCC(O)=O)NC(=O)[C@@H](CCC(O)=O)NC(=O)[C@@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H]1N(CCC1)C(=O)CNC(=O)[C@@H](N)CCC(O)=O)C1=CC=C(O)C=C1 AOXOCDRNSPFDPE-UKEONUMOSA-N 0.000 description 9
- 238000002474 experimental method Methods 0.000 description 9
- 230000013872 defecation Effects 0.000 description 7
- 241000208340 Araliaceae Species 0.000 description 6
- 241000132012 Atractylodes Species 0.000 description 6
- 235000005035 Panax pseudoginseng ssp. pseudoginseng Nutrition 0.000 description 6
- 235000003140 Panax quinquefolius Nutrition 0.000 description 6
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 6
- 229930006000 Sucrose Natural products 0.000 description 6
- 210000004369 blood Anatomy 0.000 description 6
- 239000008280 blood Substances 0.000 description 6
- 235000008434 ginseng Nutrition 0.000 description 6
- 229960004793 sucrose Drugs 0.000 description 6
- 238000012360 testing method Methods 0.000 description 6
- 208000018522 Gastrointestinal disease Diseases 0.000 description 5
- 230000001154 acute effect Effects 0.000 description 5
- 210000000436 anus Anatomy 0.000 description 5
- 230000003285 pharmacodynamic effect Effects 0.000 description 5
- 208000024891 symptom Diseases 0.000 description 5
- 241001465754 Metazoa Species 0.000 description 4
- 235000001188 Peltandra virginica Nutrition 0.000 description 4
- 238000000465 moulding Methods 0.000 description 4
- 210000002966 serum Anatomy 0.000 description 4
- 230000009278 visceral effect Effects 0.000 description 4
- 206010024642 Listless Diseases 0.000 description 3
- 210000001015 abdomen Anatomy 0.000 description 3
- 201000009840 acute diarrhea Diseases 0.000 description 3
- 238000010171 animal model Methods 0.000 description 3
- 235000006533 astragalus Nutrition 0.000 description 3
- 230000037213 diet Effects 0.000 description 3
- 230000003203 everyday effect Effects 0.000 description 3
- 239000000284 extract Substances 0.000 description 3
- 230000037406 food intake Effects 0.000 description 3
- 235000012631 food intake Nutrition 0.000 description 3
- 230000002757 inflammatory effect Effects 0.000 description 3
- 208000017971 listlessness Diseases 0.000 description 3
- 210000002381 plasma Anatomy 0.000 description 3
- 230000000638 stimulation Effects 0.000 description 3
- 206010002091 Anaesthesia Diseases 0.000 description 2
- 241000045403 Astragalus propinquus Species 0.000 description 2
- 206010006895 Cachexia Diseases 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- 239000009636 Huang Qi Substances 0.000 description 2
- 241000700157 Rattus norvegicus Species 0.000 description 2
- 210000003489 abdominal muscle Anatomy 0.000 description 2
- 210000003815 abdominal wall Anatomy 0.000 description 2
- 230000037005 anaesthesia Effects 0.000 description 2
- 230000003110 anti-inflammatory effect Effects 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 230000001684 chronic effect Effects 0.000 description 2
- 208000026500 emaciation Diseases 0.000 description 2
- 206010016256 fatigue Diseases 0.000 description 2
- 230000002550 fecal effect Effects 0.000 description 2
- 239000000706 filtrate Substances 0.000 description 2
- 230000006996 mental state Effects 0.000 description 2
- 239000002674 ointment Substances 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 230000011514 reflex Effects 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 229940076742 senna leaves Drugs 0.000 description 2
- 238000002791 soaking Methods 0.000 description 2
- 238000007619 statistical method Methods 0.000 description 2
- 230000009885 systemic effect Effects 0.000 description 2
- GOZMBJCYMQQACI-UHFFFAOYSA-N 6,7-dimethyl-3-[[methyl-[2-[methyl-[[1-[3-(trifluoromethyl)phenyl]indol-3-yl]methyl]amino]ethyl]amino]methyl]chromen-4-one;dihydrochloride Chemical compound Cl.Cl.C=1OC2=CC(C)=C(C)C=C2C(=O)C=1CN(C)CCN(C)CC(C1=CC=CC=C11)=CN1C1=CC=CC(C(F)(F)F)=C1 GOZMBJCYMQQACI-UHFFFAOYSA-N 0.000 description 1
- 206010000060 Abdominal distension Diseases 0.000 description 1
- 241000224489 Amoeba Species 0.000 description 1
- 241000228212 Aspergillus Species 0.000 description 1
- 241001061264 Astragalus Species 0.000 description 1
- 208000031648 Body Weight Changes Diseases 0.000 description 1
- 240000007124 Brassica oleracea Species 0.000 description 1
- 235000003899 Brassica oleracea var acephala Nutrition 0.000 description 1
- 235000011301 Brassica oleracea var capitata Nutrition 0.000 description 1
- 235000001169 Brassica oleracea var oleracea Nutrition 0.000 description 1
- 241000589875 Campylobacter jejuni Species 0.000 description 1
- 241000222120 Candida <Saccharomycetales> Species 0.000 description 1
- 235000006693 Cassia laevigata Nutrition 0.000 description 1
- 208000019399 Colonic disease Diseases 0.000 description 1
- 206010010774 Constipation Diseases 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 208000027534 Emotional disease Diseases 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- 208000036115 Faecal volume increased Diseases 0.000 description 1
- 206010017367 Frequent bowel movements Diseases 0.000 description 1
- 206010017533 Fungal infection Diseases 0.000 description 1
- 208000007882 Gastritis Diseases 0.000 description 1
- 241000224467 Giardia intestinalis Species 0.000 description 1
- 208000002720 Malnutrition Diseases 0.000 description 1
- 241000235395 Mucor Species 0.000 description 1
- 208000031888 Mycoses Diseases 0.000 description 1
- 241001263478 Norovirus Species 0.000 description 1
- 206010033645 Pancreatitis Diseases 0.000 description 1
- 206010057071 Rectal tenesmus Diseases 0.000 description 1
- 244000299790 Rheum rhabarbarum Species 0.000 description 1
- 235000009411 Rheum rhabarbarum Nutrition 0.000 description 1
- 241000702670 Rotavirus Species 0.000 description 1
- 241000522641 Senna Species 0.000 description 1
- 208000005718 Stomach Neoplasms Diseases 0.000 description 1
- 208000025865 Ulcer Diseases 0.000 description 1
- 206010047700 Vomiting Diseases 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 208000031975 Yang Deficiency Diseases 0.000 description 1
- 210000000683 abdominal cavity Anatomy 0.000 description 1
- 231100000215 acute (single dose) toxicity testing Toxicity 0.000 description 1
- 208000005298 acute pain Diseases 0.000 description 1
- 238000011047 acute toxicity test Methods 0.000 description 1
- 208000022531 anorexia Diseases 0.000 description 1
- 210000000702 aorta abdominal Anatomy 0.000 description 1
- 230000006399 behavior Effects 0.000 description 1
- 230000003542 behavioural effect Effects 0.000 description 1
- 230000004579 body weight change Effects 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- RNFNDJAIBTYOQL-UHFFFAOYSA-N chloral hydrate Chemical compound OC(O)C(Cl)(Cl)Cl RNFNDJAIBTYOQL-UHFFFAOYSA-N 0.000 description 1
- 229960002327 chloral hydrate Drugs 0.000 description 1
- 201000001352 cholecystitis Diseases 0.000 description 1
- 210000002932 cholinergic neuron Anatomy 0.000 description 1
- 210000001072 colon Anatomy 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 206010061428 decreased appetite Diseases 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 238000000556 factor analysis Methods 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 206010017758 gastric cancer Diseases 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 238000003304 gavage Methods 0.000 description 1
- 229940085435 giardia lamblia Drugs 0.000 description 1
- 230000037308 hair color Effects 0.000 description 1
- 230000004886 head movement Effects 0.000 description 1
- 235000012907 honey Nutrition 0.000 description 1
- 201000001371 inclusion conjunctivitis Diseases 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 208000002551 irritable bowel syndrome Diseases 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 231100001252 long-term toxicity Toxicity 0.000 description 1
- 230000001071 malnutrition Effects 0.000 description 1
- 235000000824 malnutrition Nutrition 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 210000003097 mucus Anatomy 0.000 description 1
- 208000015380 nutritional deficiency disease Diseases 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 208000024691 pancreas disease Diseases 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 231100000915 pathological change Toxicity 0.000 description 1
- 230000036285 pathological change Effects 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 210000004197 pelvis Anatomy 0.000 description 1
- 239000003208 petroleum Substances 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 210000000664 rectum Anatomy 0.000 description 1
- 230000001932 seasonal effect Effects 0.000 description 1
- 229940124513 senna glycoside Drugs 0.000 description 1
- 239000009765 shen ling bai zhu Substances 0.000 description 1
- 238000007873 sieving Methods 0.000 description 1
- 235000020374 simple syrup Nutrition 0.000 description 1
- 208000021795 small intestine disease Diseases 0.000 description 1
- 201000011549 stomach cancer Diseases 0.000 description 1
- 208000018556 stomach disease Diseases 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 238000003239 susceptibility assay Methods 0.000 description 1
- 230000009182 swimming Effects 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 210000004233 talus Anatomy 0.000 description 1
- 208000012271 tenesmus Diseases 0.000 description 1
- 206010044325 trachoma Diseases 0.000 description 1
- 231100000397 ulcer Toxicity 0.000 description 1
- 210000001113 umbilicus Anatomy 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 230000008673 vomiting Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/23—Apiaceae or Umbelliferae (Carrot family), e.g. dill, chervil, coriander or cumin
- A61K36/237—Notopterygium
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/06—Fungi, e.g. yeasts
- A61K36/07—Basidiomycota, e.g. Cryptococcus
- A61K36/076—Poria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/23—Apiaceae or Umbelliferae (Carrot family), e.g. dill, chervil, coriander or cumin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/23—Apiaceae or Umbelliferae (Carrot family), e.g. dill, chervil, coriander or cumin
- A61K36/232—Angelica
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/23—Apiaceae or Umbelliferae (Carrot family), e.g. dill, chervil, coriander or cumin
- A61K36/233—Bupleurum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/23—Apiaceae or Umbelliferae (Carrot family), e.g. dill, chervil, coriander or cumin
- A61K36/236—Ligusticum (licorice-root)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/23—Apiaceae or Umbelliferae (Carrot family), e.g. dill, chervil, coriander or cumin
- A61K36/238—Saposhnikovia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/34—Campanulaceae (Bellflower family)
- A61K36/346—Platycodon
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/484—Glycyrrhiza (licorice)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
- A61K36/538—Schizonepeta
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/75—Rutaceae (Rue family)
- A61K36/752—Citrus, e.g. lime, orange or lemon
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/12—Antidiarrhoeals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/331—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using water, e.g. cold water, infusion, tea, steam distillation or decoction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/333—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using mixed solvents, e.g. 70% EtOH
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Mycology (AREA)
- Medical Informatics (AREA)
- Alternative & Traditional Medicine (AREA)
- Biotechnology (AREA)
- Botany (AREA)
- Microbiology (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
The invention belongs to the technical field of traditional Chinese medicines, and particularly relates to a traditional Chinese medicine composition for treating abdominal pain and diarrhea. The traditional Chinese medicine composition is mainly prepared from notopterygium root, radix angelicae pubescentis, poria cocos, divaricate saposhnikovia root, schizonepeta, ligusticum wallichii, platycodon grandiflorum, radix bupleuri, radix peucedani, fructus aurantii and liquorice. The traditional Chinese medicine composition can reduce gastrointestinal tract viscera sensitivity, regulate neurotransmitter excitability, reduce the release of pain substances, improve intestinal inflammation and also has the effect of strengthening spleen.
Description
Technical Field
The invention relates to a composition, in particular to a traditional Chinese medicine composition for treating and/or relieving abdominal pain and diarrhea, and belongs to the technical field of traditional Chinese medicines.
Background
Diarrhea (diarrhea) is commonly called "diarrhea," and refers to the change in defecation habits and stool characteristics. It is manifested as increased frequency of defecation, increased stool volume, unformed, loose or liquid stool, sometimes with purulent blood or with undigested material and fat. It is divided into acute and chronic types according to the course of disease and the degree of urgency and severity of disease. The cause of diarrhea is many, and not only the disease of the intestinal tract itself but also the disease or injury outside or systemic intestine can cause diarrhea. The typical clinical manifestations of diarrhea are mainly: (1) the defecation frequency is changed, which is shown in that the defecation frequency is increased, and acute diarrhea is defecated for several times or even dozens of times every day; (2) the nature of the excrement is changed, the excrement is thin or is water-like, and mucus and purulent blood can be brought in the excrement; (3) abdominal pain, acute diarrhea often has abdominal pain, and especially infectious diarrhea is more obvious. Diarrhea and pain of small intestine diseases are usually around umbilicus, and abdominal pain is not obviously relieved after defecation. Pain caused by colon diseases is mostly in the lower abdomen, and pain after defecation can be relieved; (4) tenesmus, i.e. feeling of anal distention, frequent defecation and incomplete defecation; (5) otherwise, some patients may have alternating diarrhea and constipation, vomiting, etc.
The term "abdominal pain" refers to the pain occurring in the area below the gastric cavity and above the pubic hairline. The abdominal pain is mainly caused by qi stagnation, obstruction of collaterals or malnutrition of the meridians and unsmooth circulation of qi and blood due to exogenous seasonal pathogens, improper diet, emotional disorders and constitutional yang deficiency. Abdominal pain (abdominal pain) is a common clinical symptom, and is usually caused by pathological changes of organs in abdominal cavity, chest diseases and systemic diseases. Abdominal pain can be divided into acute and chronic abdominal pain. Acute abdominal pain is acute and the course of disease is short; the chronic abdominal pain has a slow onset and a long course. In clinic, the location of abdominal pain, nature of pain, onset urgency, duration, and accompanying symptoms should be analyzed.
Abdominal pain is caused by various gastrointestinal diseases, such as dysentery and acute gastritis in acute gastrointestinal diseases, ulcer, gastric cancer, pancreatitis, cholecystitis, irritable bowel syndrome and the like in chronic gastrointestinal diseases, so that the abdominal pain is one of the most common symptoms of gastrointestinal diseases and is an important signal for gastrointestinal diseases.
Disclosure of Invention
The inventor explains that the invention is further developed on the basis of the existing product 'Jingfang granules', and the new application of the Jingfang granules comes from clinical use feedback. Part of patients with cold due to wind-cold type of digestive tract diseases feedback that symptoms such as abdominal pain and diarrhea caused by the digestive tract diseases are also improved during taking Jingfang granules.
Based on the clinical use feedback, the inventor further researches and develops the new application of the Jingfang granules and the prescription thereof in treating and/or improving the abdominal pain and diarrhea.
One of the purposes of the invention is to provide a traditional Chinese medicine composition for treating and/or improving abdominal pain and diarrhea, which is mainly prepared from notopterygium root, radix angelicae pubescentis, poria cocos, radix sileris, schizonepeta, ligusticum wallichii, platycodon grandiflorum, radix bupleuri, radix peucedani, fructus aurantii and liquorice.
The diarrhea of the invention mainly comprises infectious diarrhea and non-infectious diarrhea.
Preferably, the infectious diarrhea mainly refers to diarrhea caused by infection with one or more of bacteria, viruses, fungi and parasites; further preferably, the bacteria may be diarrhea causing escherichia coli, campylobacter jejuni, etc., the viruses may be rotavirus, norovirus, etc., the parasites may be giardia lamblia, amoeba, etc., and the fungal infection may be candida, aspergillus, mucor, etc.
Preferably, the non-infectious diarrhea is diarrhea caused by one or more of dietary factors, pharmaceutical factors, climatic factors, and disease factors.
Further preferably, the disease factors may be gastric diseases, intestinal diseases, pancreatic diseases, liver and gall diseases; the abdominal pain mainly refers to the abdominal pain caused by digestive tract diseases; or abdominal pain associated with acute diarrhea.
The second purpose of the present invention is to provide the specific composition of the above traditional Chinese medicine composition, namely, the traditional Chinese medicine composition is mainly prepared from the following raw materials:
preferably, the traditional Chinese medicine composition is mainly prepared from the following raw materials:
further preferably, the traditional Chinese medicine composition is mainly prepared from the following raw materials:
the invention also aims to provide a preparation method of the traditional Chinese medicine composition, which mainly comprises the following steps:
step A: distilling herba Schizonepetae, radix Saposhnikoviae, Notopterygii rhizoma, radix Angelicae Pubescentis, radix Peucedani, rhizoma Ligustici Chuanxiong, and fructus Aurantii to obtain volatile oil, and collecting the residue, rhizoma Ligustici Chuanxiong, and fructus Aurantii water solution;
and B: b, preparing the distilled water solution of the ligusticum wallichii and the fructus aurantii obtained in the step A into a 10-40% ethanol solution for later use;
and C: mixing Poria, the distilled rhizoma Ligustici Chuanxiong obtained in step A, and fructus Aurantii residue, percolating with the ethanol solution obtained in step B, and collecting percolate;
step D: decocting radix bupleuri, platycodon grandiflorum, liquorice, the distilled schizonepeta obtained in the step A, divaricate saposhnikovia root, notopterygium root, radix angelicae pubescentis and radix peucedani dregs in water, and concentrating the decoction for later use;
step E: and D, mixing the percolate obtained in the step C and the decoction obtained in the step D, concentrating, and adding the volatile oil obtained in the step A to obtain the composition.
Preferably, the preparation method mainly comprises the following steps:
step A: distilling herba Schizonepetae, radix Saposhnikoviae, Notopterygii rhizoma, radix Angelicae Pubescentis, radix Peucedani, rhizoma Ligustici Chuanxiong, and fructus Aurantii to obtain volatile oil, and collecting the residue, rhizoma Ligustici Chuanxiong, and fructus Aurantii water solution;
and B: b, preparing the distilled water solution of the ligusticum wallichii and the fructus aurantii obtained in the step A into 15-30% ethanol solution for later use;
and C: mixing Poria, the distilled rhizoma Ligustici Chuanxiong obtained in step A, and fructus Aurantii residue, percolating with the ethanol solution obtained in step B, and collecting percolate;
step D: decocting radix bupleuri, platycodon grandiflorum, liquorice, the distilled schizonepeta obtained in the step A, divaricate saposhnikovia root, notopterygium root, radix angelicae pubescentis and radix peucedani dregs in water, and concentrating the decoction into thick paste for later use;
step E: and D, mixing the percolate obtained in the step C and the thick paste obtained in the step D, concentrating the mixture into clear paste, and adding the volatile oil obtained in the step A to obtain the ointment.
Further preferably, the preparation method mainly comprises the following steps:
step A: distilling herba Schizonepetae, radix Saposhnikoviae, Notopterygii rhizoma, radix Angelicae Pubescentis, radix Peucedani, rhizoma Ligustici Chuanxiong, and fructus Aurantii to obtain volatile oil, and collecting the residue, rhizoma Ligustici Chuanxiong, and fructus Aurantii water solution;
and B: b, preparing the distilled water solution of the ligusticum wallichii and the fructus aurantii obtained in the step A into a 25% ethanol solution for later use;
and C: mixing Poria, the distilled rhizoma Ligustici Chuanxiong obtained in step A, and fructus Aurantii residue, percolating with the ethanol solution obtained in step B, and collecting percolate;
step D: decocting radix bupleuri, platycodon grandiflorum, liquorice, the distilled schizonepeta obtained in the step A, divaricate saposhnikovia root, notopterygium root, radix angelicae pubescentis and radix peucedani dregs in water, and concentrating the decoction into thick paste for later use;
step E: and D, mixing the percolate obtained in the step C and the thick paste obtained in the step D, concentrating the mixture into clear paste, and adding the volatile oil obtained in the step A to obtain the ointment.
The fourth purpose of the invention is to provide a traditional Chinese medicine preparation, which contains the traditional Chinese medicine composition and pharmaceutically acceptable auxiliary materials, and the traditional Chinese medicine preparation can be a clinically acceptable oral preparation;
preferably, the clinically acceptable oral preparation is one or more of pills, capsules, tablets, granules or liquid oral preparations;
even more preferably, the oral formulation is a granule.
The invention also provides application of the Jingfang granules in preparing medicaments for treating and/or improving abdominal pain and diarrhea.
Compared with the prior art, the invention has the following remarkable technical effects:
1. the traditional Chinese medicine composition can reduce the AWR score of rats when CRD pressure is 20mmHg, 30mmHg and 40mmHg, and reduce gastrointestinal tract visceral sensitivity; it also can regulate the excitability of the neurotransmitters 5-HT and SP, reduce the release of the pain-causing substance SP, and stimulate cholinergic neurons.
2. The traditional Chinese medicine composition can improve the content of motilin and gastrin of diarrhea rats, can reduce the content of inflammatory factors, and can improve the content of inflammation-inhibiting factors.
DETAILED DESCRIPTION OF EMBODIMENT (S) OF INVENTION
EXAMPLE 1 preparation of granules
Prescription:
the preparation method comprises the following steps:
step A: respectively distilling herba Schizonepetae, radix Saposhnikoviae, Notopterygii rhizoma, radix Angelicae Pubescentis, radix Peucedani, rhizoma Ligustici Chuanxiong, and fructus Aurantii to obtain volatile oil, and respectively distilling the residue, rhizoma Ligustici Chuanxiong, and fructus Aurantii to obtain water solution;
and B: b, preparing the distilled water solution of the ligusticum wallichii and the fructus aurantii obtained in the step A into a 25% ethanol solution for later use;
and C: mixing Poria, the distilled rhizoma Ligustici Chuanxiong obtained in step A, and fructus Aurantii residue, percolating with the ethanol solution obtained in step B, and collecting percolate;
step D: decocting radix bupleuri, platycodon grandiflorum, liquorice, the distilled schizonepeta obtained in the step A, divaricate saposhnikovia root, notopterygium root, radix angelicae pubescentis and radix peucedani dregs with water twice, each time for 1.5 hours, combining decoctions obtained in the two times, filtering and concentrating into thick paste for later use;
step E: and D, mixing the percolate obtained in the step C and the thick paste obtained in the step D, standing, filtering, concentrating into clear paste, adding a proper amount of cane sugar, uniformly mixing, preparing into granules, drying, adding the volatile oil obtained in the step A, and uniformly mixing to obtain the traditional Chinese medicine.
Example 2 preparation of granules
Prescription:
the preparation method is the same as example 1.
Example 3 oral liquid preparation
Prescription:
the preparation method comprises the following steps:
step A: respectively distilling herba Schizonepetae, radix Saposhnikoviae, Notopterygii rhizoma, radix Angelicae Pubescentis, radix Peucedani, rhizoma Ligustici Chuanxiong, and fructus Aurantii to obtain volatile oil, and respectively distilling the residue, rhizoma Ligustici Chuanxiong, and fructus Aurantii to obtain water solution;
and B: b, preparing the distilled water solution of the ligusticum wallichii and the fructus aurantii obtained in the step A into a 10% ethanol solution for later use;
and C: mixing Poria, the distilled rhizoma Ligustici Chuanxiong obtained in step A, and fructus Aurantii residue, percolating with the ethanol solution obtained in step B, and collecting percolate;
step D: decocting radix bupleuri, platycodon grandiflorum, liquorice, the distilled schizonepeta obtained in the step A, divaricate saposhnikovia root, notopterygium root, radix angelicae pubescentis and radix peucedani dregs with water twice, each time for 1.5 hours, combining decoctions obtained in the two times, filtering and concentrating into thick paste for later use;
step E: and D, mixing the percolate obtained in the step C and the thick paste obtained in the step D, standing, filtering, concentrating into clear paste, adding a proper amount of sucrose, mixing uniformly, adding the volatile oil obtained in the step A, mixing uniformly, and adding water to 1000ml to obtain the traditional Chinese medicine composition.
Example 4 syrup preparation
Prescription:
the preparation method comprises the following steps:
step A: respectively distilling herba Schizonepetae, radix Saposhnikoviae, Notopterygii rhizoma, radix Angelicae Pubescentis, radix Peucedani, rhizoma Ligustici Chuanxiong, and fructus Aurantii to obtain volatile oil, and respectively distilling the residue, rhizoma Ligustici Chuanxiong, and fructus Aurantii to obtain water solution;
and B: b, preparing the distilled water solution of the ligusticum wallichii and the fructus aurantii obtained in the step A into a 40% ethanol solution for later use;
and C: mixing Poria, the distilled rhizoma Ligustici Chuanxiong obtained in step A, and fructus Aurantii residue, percolating with the ethanol solution obtained in step B, and collecting percolate;
step D: decocting radix bupleuri, platycodon grandiflorum, liquorice, the distilled schizonepeta obtained in the step A, divaricate saposhnikovia root, notopterygium root, radix angelicae pubescentis and radix peucedani dregs with water twice, each time for 1.5 hours, combining decoctions obtained in the two times, filtering and concentrating into thick paste for later use;
step E: and D, mixing the percolate obtained in the step C and the thick paste obtained in the step D, standing, filtering, concentrating into clear paste, adding a proper amount of cane sugar, mixing uniformly, adding 500ml of the volatile oil and the simple syrup obtained in the step A, mixing uniformly, standing, filtering, and adding water to 1000ml to obtain the traditional Chinese medicine.
EXAMPLE 5 tablet preparation
Prescription:
the preparation method comprises the following steps:
step A: respectively distilling herba Schizonepetae, radix Saposhnikoviae, Notopterygii rhizoma, radix Angelicae Pubescentis, radix Peucedani, rhizoma Ligustici Chuanxiong, and fructus Aurantii to obtain volatile oil, and respectively distilling the residue, rhizoma Ligustici Chuanxiong, and fructus Aurantii to obtain water solution;
and B: b, preparing the distilled water solution of the ligusticum wallichii and the fructus aurantii obtained in the step A into a 15% ethanol solution for later use;
and C: mixing Poria, the distilled rhizoma Ligustici Chuanxiong obtained in step A, and fructus Aurantii residue, percolating with the ethanol solution obtained in step B, and collecting percolate;
step D: decocting radix bupleuri, platycodon grandiflorum, liquorice, the distilled schizonepeta obtained in the step A, divaricate saposhnikovia root, notopterygium root, radix angelicae pubescentis and radix peucedani dregs with water twice, each time for 1.5 hours, combining decoctions obtained in the two times, filtering and concentrating into thick paste for later use;
step E: and D, mixing the percolate obtained in the step C and the thick paste obtained in the step D, standing, filtering, concentrating into clear paste, adding a proper amount of cane sugar, uniformly mixing, granulating, drying, adding the volatile oil obtained in the step A, uniformly mixing, granulating, adding a proper amount of auxiliary materials, uniformly mixing, and tabletting to obtain the traditional Chinese medicine.
EXAMPLE 6 Capsule preparation
Prescription:
step A: respectively distilling herba Schizonepetae, radix Saposhnikoviae, Notopterygii rhizoma, radix Angelicae Pubescentis, radix Peucedani, rhizoma Ligustici Chuanxiong, and fructus Aurantii to obtain volatile oil, and respectively distilling the residue, rhizoma Ligustici Chuanxiong, and fructus Aurantii to obtain water solution;
and B: b, preparing the distilled water solution of the ligusticum wallichii and the fructus aurantii obtained in the step A into a 30% ethanol solution for later use;
and C: mixing Poria, the distilled rhizoma Ligustici Chuanxiong obtained in step A, and fructus Aurantii residue, percolating with the ethanol solution obtained in step B, and collecting percolate;
step D: decocting radix bupleuri, platycodon grandiflorum, liquorice, the distilled schizonepeta obtained in the step A, divaricate saposhnikovia root, notopterygium root, radix angelicae pubescentis and radix peucedani dregs with water twice, each time for 1.5 hours, combining decoctions obtained in the two times, filtering and concentrating into thick paste for later use;
step E: and D, mixing the percolate obtained in the step C and the thick paste obtained in the step D, standing, filtering, concentrating into clear paste, adding a proper amount of cane sugar, uniformly mixing, granulating, drying, adding the volatile oil obtained in the step A, uniformly mixing, granulating, drying, crushing and encapsulating to obtain the capsule.
EXAMPLE 7 pellet preparation
Prescription:
the preparation method comprises the following steps:
step A: respectively distilling herba Schizonepetae, radix Saposhnikoviae, Notopterygii rhizoma, radix Angelicae Pubescentis, radix Peucedani, rhizoma Ligustici Chuanxiong, and fructus Aurantii to obtain volatile oil, and respectively distilling the residue, rhizoma Ligustici Chuanxiong, and fructus Aurantii to obtain water solution;
and B: b, preparing the distilled water solution of the ligusticum wallichii and the fructus aurantii obtained in the step A into a 25% ethanol solution for later use;
and C: mixing Poria, the distilled rhizoma Ligustici Chuanxiong obtained in step A, and fructus Aurantii residue, percolating with the ethanol solution obtained in step B, and collecting percolate;
step D: decocting radix bupleuri, platycodon grandiflorum, liquorice, the distilled schizonepeta obtained in the step A, divaricate saposhnikovia root, notopterygium root, radix angelicae pubescentis and radix peucedani dregs with water twice, each time for 1.5 hours, combining decoctions obtained in the two times, filtering and concentrating into thick paste for later use;
step E: and D, mixing the percolate obtained in the step C and the thick paste obtained in the step D, standing, filtering, concentrating into clear paste, adding a proper amount of cane sugar, uniformly mixing, preparing into granules, drying, adding the volatile oil obtained in the step A, uniformly mixing, drying, crushing, sieving, adding 40-60 g of refined honey and a proper amount of water, pelleting, and drying to obtain the traditional Chinese medicine.
Second, pharmacodynamic test
In order to verify the efficacy of the traditional Chinese medicine composition in treating or improving the abdominal pain and the diarrhea, the inventor carries out related pharmacodynamic test research. It should be noted that the medicines selected in the pharmacodynamic tests below are the medicines obtained by the representative formula and the preparation method thereof; the inventor also conducts pharmacodynamic experiments on the medicines obtained by the other formulas and the preparation methods, and the experimental results show that the medicines obtained by the other formulas and the preparation methods have the same or similar effects, but the medicines are not exhaustive due to space limitations.
In addition, the following only takes part of animal models as examples to verify the efficacy of the present invention, the inventor also performs related pharmacodynamic experiments on abdominal pain and diarrhea caused by other reasons, and the experimental results show that the present invention has the same or similar effects, and the experiments are not exhaustive.
The inventor explains that the following experimental studies are carried out on the basis of the safety of the drug proved by acute toxicity tests and long-term toxicity tests, and the administration dose in the experimental studies is within a safe dose range.
First, the Chinese medicinal composition of the invention has the treatment effect on abdominal pain rats
1 Material
1.1 animals:
wistar rat, SPF grade, 180-220 g, laboratory animal license number: SYXK (lu) 20180008, provided by lumnan pharmaceutical group ltd, was acclimatized for one week prior to the experiment.
1.2 drugs, reagents
1.2.1 medicaments
Granules obtained in examples 1 and 2 of the present invention
Astragalus Jianzhong pills (Chinese medicine standard Z20025427)
1.2.3 dosage
Example 1 granules: 2.025g/kg (Low dose), 4.05g/kg (Medium dose), 8.1g/kg (high dose)
Example 2 granules: 4.05g/kg
Astragalus membranaceus Jianzhong pill: 1.62g/kg
2. Experimental methods
2.1 molding mode:
the molding process is divided into two major stages (both are free to drink water).
The first stage is that in the first 6 days, refined lard is fed for one day by 2mL/200g, and cabbage is fed for two days by l0g/200 g; swimming in 38 ℃ warm water every day until fatigue;
in the second stage, the water extract of the senna leaves is added for 7 to 21 days, and 2mL/200g of the water extract of the senna leaves is added every day.
The preparation method of the senna water extract comprises the following steps: soaking folium sennae in water for 30min, boiling for about 10min, filtering, and concentrating the filtrate to obtain 1:1 water extractive solution.
2.2 grouping and administration
60 successfully molded rats, a random model group, an astragalus mongholicus and Jianzhong pill group, three dose groups of example 1 (low, medium and high), and 10 rats in example 2 are selected. Another 10 rats were fed normally and were blank groups.
From experiment 22d, rats in each administration group were gavaged with the corresponding drug, and the blank group and the model group were gavaged with distilled water in equal amounts for 14 d.
3. Detecting the index
3.1 general case
In the experimental process, the appearance and activity conditions of rats, such as listlessness, crouching, bunching, slow reaction, withered and scattered fur, dirty anus, diet reduction, emaciation and the like, are observed. Before and after dosing, food intake and body weight changes were recorded.
3.2 visceral sensitivity assay
No water is forbidden 24h before detection. After ether anesthesia, a catheter lubricated with petroleum was inserted through the anus, with the balloon distal 1cm from the anus, and the catheter was fixed to the tail of the rat. After the rat revives, the rat is placed in a special plastic cage, and the rat can only move up and down but cannot move back and forth and turn around. After 30min acclimation period, changes in visceral sensitivity of rats were reflected by observation of abdominal wall withdrawal reflex (AWR) scores under colorectal distension stimulation under different pressure conditions (20mmHg, 30mmHg, 40 mmHg). Colorectal distension (CRD) stimulation each CRD pressure was 20s in duration and repeated 3 times, and the measured AWR scores were averaged over the last three times as the final abdominal wall withdrawal reflex (AWR) score at that distension pressure.
Grading standard: 0 point, the rat has no behavioral response to colorectal distension; 1 minute, the body is still when the colorectal is expanded, and the head movement is reduced or raised; 2 min, abdominal muscles contract when the colorectal is expanded, but the abdomen is not lifted off the table top; 3, abdominal muscle contracts and the abdomen is lifted off the table when the colorectal is expanded, and the patient is hoarsed; when the colon and rectum are expanded, the pelvis is lifted, and the body is arched.
3.3 measurement of the content of Substance P (SP), tumor necrosis factor alpha (TNF-alpha), neurotransmitter 5-hydroxytryptamine (5-HT) in blood
Collecting blood from rat vein, centrifuging, collecting blood plasma, and measuring contents of Substance P (SP) and neurotransmitter 5-hydroxytryptamine (5-HT) in blood plasma;
rats were bled intravenously, sera were separated and TNF- α levels in sera were determined.
3.4 statistical treatment
Statistical analysis is carried out on the obtained data by adopting SPSS22.0 software, and the data is measured
The results are shown in the following table, wherein the comparison among the groups is carried out by adopting one-factor analysis of variance, and the comparison between the two groups is carried out by adopting a T test mode. With P<A difference of 0.05 is statistically significant.
4. Results and conclusions
4.1 general case
Before the molding is started, the fur of each group of rats is white and glossy, and the mental state is good. After the model is built, rats show symptoms of listlessness, squinting, crouching, slow reaction, unstable walking, withered and lusterless fur, dirty anus, diet reduction, emaciation and the like
4.2 evaluation of visceral sensitivity
Compared with the blank group, the AWR score of the model group pups is obviously increased (p <0.01) under the stimulation of various CRD pressures (20mmHg, 30mmHg and 40 mmHg);
the AWR score was significantly reduced (p <0.05 or p <0.01) at CRD pressures of 20mmHg, 30mmHg and 40mmHg for each dosing group of rats compared to the model group.
Table 1 comparison of AWR scores at different expansion volumes for each group of rats (
n＝10)
Note: in contrast to the blank group,△P＜0.05，#P＜0.01；
in contrast to the model set,@P＜0.05，*P＜0.01；
compared with the radix astragali Jianzhong pill group,&P＜0.05。
4.3 Effect on the levels of pain-causing Substances P (SP), tumor necrosis factor alpha (TNF-alpha), neurotransmitter 5-hydroxytryptamine (5-HT)
Compared with the blank group, the levels of SP, 5-HT and TNF-alpha in blood serum of the rats in the model group are obviously increased (P is less than 0.01); compared with the model group, the levels of SP, 5-HT and TNF-alpha in blood serum of rats in each administration group are reduced (p <0.05, p < 0.01).
TABLE 2 comparison of the SP, 5-HT in plasma and TNF-alpha content in serum of the various groups of rats: (
n＝10)
Note: in contrast to the blank group,△P＜0.05，#P＜0.01；
in contrast to the model set,@P＜0.05，*P＜0.01；
compared with the radix astragali Jianzhong pill group,&P＜0.05。
secondly, the traditional Chinese medicine composition has the treatment effect on diarrhea rats
1 Material
1.1 animals:
wistar rat, SPF grade, 180-220 g, laboratory animal license number: SYXK (lu) 20180008, provided by lumnan pharmaceutical group ltd, was acclimatized for one week prior to the experiment.
1.2 drugs, reagents
1.2.1 medicaments
Granules obtained in examples 1 and 2 of the present invention
Shenling Baizhu Wan (Chinese medicine standard character Z37020850)
1.2.3 dosage
Example 1 granules: 2.025g/kg (Low dose), 4.05g/kg (Medium dose), 8.1g/kg (high dose)
Example 2 granules: 5.85g/kg
Ginseng, poria cocos and bighead atractylodes rhizome pills: 1.62g/kg
2. Experimental methods
2.1 molding mode:
cutting radix et rhizoma Rhei, adding appropriate amount of water, soaking in oven at 60-80 deg.C overnight, filtering, and concentrating the filtrate to obtain 2g/ml medicinal liquid. The rats are administrated with rhubarb liquid at a dose of 20ml/kg for intragastric administration 2 times a day, 1 time respectively in the morning and evening, and are molded for 10 days. Diarrhea in rats was observed and recorded.
2.2 grouping
60 rats successfully molded are randomly divided into a model group, a ginseng, poria and bighead atractylodes rhizome pill group, three dose groups of example 1 (high, medium and low), and 10 rats of example 2. Another 10 rats fed normally were selected as a blank group.
From day 11 onward, rats in each administration group were gavaged with the corresponding drug, and rats in the blank group and model group were gavaged with an equal amount of physiological saline for 7 days continuously.
3. Detecting the index
3.1 general State Observation in rats
The general state of the rats including hair gloss, mental state, food intake, activity, etc. was observed before administration in the morning and the body mass of the rats was recorded.
3.2 fecal Water content and diarrhea grade score
Collecting fresh feces of each rat before gavage administration in the morning on days 0, 7, 10 and 17 of the experiment, drying the fresh feces in an oven at 105 ℃ for 5 hours, measuring the moisture content of the feces, grading the feces form of each rat, and finally calculating the average value of all groups.
The degree of diarrhea in rats was scored on the following scale: 0 points indicate no diarrhea, normal stool, cylindrical; 1 point indicates diarrhea, thin, soft and tangible feces; 2 points indicate diarrhea, sticky feces, unformed feces and high water content; 3 points indicate diarrhea, liquid feces, unformed feces and watery feces.
Moisture content of feces (wet mass before drying-dry mass after drying)/wet mass before drying × 100%.
3.3 determination of Motilin (MTL), Gastrin (GAS), TNF-alpha, IL-10
After the last administration, the administration groups are fasted and not forbidden for 12 hours, blood is taken from abdominal aorta after anesthesia by 10% chloral hydrate, centrifugation is carried out, serum is taken, and the MTL and GAS levels and the contents of inflammatory factors TNF-alpha and IL-10 of each sample are measured by an ELISA method (the operation is carried out according to a kit method).
3.4 statistical treatment
Statistical analysis is carried out on the obtained data by adopting SPSS22.0 software, and the data is measured
The results of the two groups are shown in the specification, and the two groups are analyzed by a T test mode. With P<0.05 difference is statistically significant。
4. Results and conclusions
4.1 Effect on rat behavioral State and body Mass
After the model is made, the rats gradually suffer from the conditions of listlessness, trachoma and lassitude, anorexia, loose stool, dirty and lusterless hair color, fear of cold and preference for pricking, excrement stuck to the anus and the like along with the prolongation of the model making time, and the proctoptosis phenomenon of individual rats occurs; the rat body mass shows a descending trend, and compared with a blank group, the difference is significant (P is less than 0.01).
After the administration treatment, the fur of each administration group of rats is bright, active and active, the energy is vigorous, the forms of the food intake and the excrement are relatively normal, the body mass is obviously increased, and the difference is significant (P is less than 0.05 or P is less than 0.01) compared with that of a model group; compared with each administration group, the difference is not significant (P is more than 0.05).
TABLE 3 comparison of the results of the variation of body constitution of rats in each group: (
n＝10，g)
Note: in contrast to the blank group,#P＜0.01；
in contrast to the model set,@P＜0.05，*P＜0.01；
4.2 fecal Water content and diarrhea grade score
After the model is made, the moisture content of the rat feces is obviously increased, and compared with a blank group, the difference is significant (P is less than 0.01), and the rat feces are loose and not shaped, and the diarrhea score is obviously increased.
After the treatment, the moisture content of the feces of the rats in each administration group is obviously reduced, the diarrhea score is also obviously reduced, and the difference is significant compared with that in the model group (P is less than 0.01).
Table 4 comparison of stool water content results for various groups of rats (a)
n＝10，％)
Note: in contrast to the blank group,#P＜0.01；
in contrast to the model set,*P＜0.01；
compared with the ginseng, tuckahoe and white atractylodes rhizome pill group,&P＜0.05。
TABLE 5 comparison of diarrhea rating scores for rats in each group: (
n is 10 minutes)
Note: in contrast to the model set,*P＜0.01；
compared with the ginseng, tuckahoe and white atractylodes rhizome pill group,&P＜0.05，￥P＜0.01。
4.3 Effect on Motilin (MTL), Gastrin (GAS)
Compared with the blank group, the motilin and the gastrin of the model group are obviously reduced, and the difference is significant (P is less than 0.01).
After the administration treatment, the motilin and the gastrin of rats in each administration group are obviously increased, and the difference has obvious difference compared with a model group (P <0.01)
TABLE 6 comparison of MTL and GAS content in rats of various groups: (
n＝10)
Note: in contrast to the blank group,△P＜0.05，#P＜0.01；
and model groupIn comparison, the method has the advantages that,*P＜0.01；
compared with the ginseng, tuckahoe and white atractylodes rhizome pill group,&P＜0.05。
4.4 Effect on inflammatory factors TNF-alpha, IL-10
Compared with the blank group, the TNF-alpha of the model group is obviously increased (P <0.01), and the inflammation is increased.
After the administration of the treatment, the TNF-alpha of rats in each administration group is reduced, and compared with a model group, the difference is significant (P is less than 0.01).
The anti-inflammatory factor IL-10 in the model group was significantly reduced (P <0.01) compared to the blank group.
After the administration treatment, the anti-inflammatory factor IL-10 of rats in each administration group is obviously increased (P is less than 0.05 or P is less than 0.01).
TABLE 7 comparison of stool water content results for various groups of rats: (
n＝10)
Note: in contrast to the blank group,#P＜0.01；
in contrast to the model set,@P＜0.05，*P＜0.01；
compared with the ginseng, tuckahoe and white atractylodes rhizome pill group,&P＜0.05。
Claims (10)
1. a Chinese medicinal composition is prepared from Notopterygii rhizoma, radix Angelicae Pubescentis, Poria, radix Saposhnikoviae, herba Schizonepetae, rhizoma Ligustici Chuanxiong, radix Platycodi, bupleuri radix, radix Peucedani, fructus Aurantii, and Glycyrrhrizae radix, and can be used for treating and/or improving abdominal pain and diarrhea.
2. The use of claim 1, wherein the diarrhea comprises infectious diarrhea, non-infectious diarrhea.
3. The use according to claim 2, wherein the infectious diarrhea is diarrhea caused by infection with one or more of bacteria, viruses, fungi, and parasites.
4. The use of claim 2, wherein the non-infectious diarrhea is diarrhea caused by one or more of dietary factors, pharmaceutical factors, climatic factors, and disease factors.
5. The use of claim 4, wherein the disease agent includes, but is not limited to, gastric disease, intestinal disease, pancreatic disease, hepatobiliary disease.
6. The use of claim 1, wherein the abdominal pain is an abdominal pain caused by a disease of the digestive tract.
7. The use of any one of claims 1-6, wherein the traditional Chinese medicine composition is prepared from the following raw materials:
preferably, the traditional Chinese medicine composition is mainly prepared from the following raw materials:
further preferably, the traditional Chinese medicine composition is mainly prepared from the following raw materials:
8. a Chinese medicinal preparation, which is characterized by comprising the Chinese medicinal composition as claimed in any one of claims 1 to 4 and pharmaceutically acceptable auxiliary materials; preferably, the traditional Chinese medicine preparation is a clinically acceptable oral preparation; further preferably, the clinically acceptable oral preparation is one or more of pills, capsules, tablets, granules or liquid oral preparations; further preferably, the granules are Jingfang granules.
9. Use of the Jingfang granules of claim 8 in the manufacture of a medicament for treating and/or ameliorating abdominal pain, diarrhea.
10. A method for preparing the Chinese medicinal composition of any one of claims 1 to 7, wherein the method comprises the following steps:
step A: distilling herba Schizonepetae, radix Saposhnikoviae, Notopterygii rhizoma, radix Angelicae Pubescentis, radix Peucedani, rhizoma Ligustici Chuanxiong, and fructus Aurantii to obtain volatile oil, and collecting the residue, rhizoma Ligustici Chuanxiong, and fructus Aurantii water solution;
and B: b, preparing the distilled water solution of the ligusticum wallichii and the fructus aurantii obtained in the step A into a 10-40% ethanol solution for later use; and C: mixing Poria, the distilled rhizoma Ligustici Chuanxiong obtained in step A, and fructus Aurantii residue, percolating with the ethanol solution obtained in step B, and collecting percolate;
step D: decocting radix bupleuri, platycodon grandiflorum, liquorice, the distilled schizonepeta obtained in the step A, divaricate saposhnikovia root, notopterygium root, radix angelicae pubescentis and radix peucedani dregs in water, and concentrating the decoction for later use;
step E: and D, mixing the percolate obtained in the step C and the decoction obtained in the step D, concentrating, and adding the volatile oil obtained in the step A to obtain the composition.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202010815618.9A CN114073731A (en) | 2020-08-14 | 2020-08-14 | A Chinese medicinal composition for treating abdominal pain and diarrhea |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202010815618.9A CN114073731A (en) | 2020-08-14 | 2020-08-14 | A Chinese medicinal composition for treating abdominal pain and diarrhea |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN114073731A true CN114073731A (en) | 2022-02-22 |
Family
ID=80280456
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202010815618.9A Pending CN114073731A (en) | 2020-08-14 | 2020-08-14 | A Chinese medicinal composition for treating abdominal pain and diarrhea |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN114073731A (en) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN114146122A (en) * | 2020-09-08 | 2022-03-08 | 鲁南制药集团股份有限公司 | Traditional Chinese medicine composition for treating anorexia |
| CN114272295A (en) * | 2020-09-27 | 2022-04-05 | 鲁南制药集团股份有限公司 | Traditional Chinese medicine composition for treating diabetic acromelic gangrene |
Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101361952A (en) * | 2008-09-19 | 2009-02-11 | 何茁 | Traditional Chinese medicine preparation for treating cold |
| CN101584745A (en) * | 2009-06-29 | 2009-11-25 | 北京大北农科技集团股份有限公司 | Preparation for new antivirus Chinese medicine formulation for animal |
| CN101664467A (en) * | 2008-09-03 | 2010-03-10 | 天津生机集团股份有限公司 | Microbial fermentation preparation of Jingfang toxicity-removing composition |
| CN102362909A (en) * | 2011-06-29 | 2012-02-29 | 纽素乐必佳（天津）药业集团有限公司 | Method for preparing schizonepeta and divaricate saposhnikovia root oral liquid for removing toxin |
| CN103251714A (en) * | 2013-04-02 | 2013-08-21 | 余姚市禽畜病防治研究所 | Chinese medicinal composition treating duck Tembusu virus |
| CN113995788A (en) * | 2020-07-28 | 2022-02-01 | 鲁南制药集团股份有限公司 | Composition for protecting liver and preparation process thereof |
-
2020
- 2020-08-14 CN CN202010815618.9A patent/CN114073731A/en active Pending
Patent Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101664467A (en) * | 2008-09-03 | 2010-03-10 | 天津生机集团股份有限公司 | Microbial fermentation preparation of Jingfang toxicity-removing composition |
| CN101361952A (en) * | 2008-09-19 | 2009-02-11 | 何茁 | Traditional Chinese medicine preparation for treating cold |
| CN101584745A (en) * | 2009-06-29 | 2009-11-25 | 北京大北农科技集团股份有限公司 | Preparation for new antivirus Chinese medicine formulation for animal |
| CN102362909A (en) * | 2011-06-29 | 2012-02-29 | 纽素乐必佳（天津）药业集团有限公司 | Method for preparing schizonepeta and divaricate saposhnikovia root oral liquid for removing toxin |
| CN103251714A (en) * | 2013-04-02 | 2013-08-21 | 余姚市禽畜病防治研究所 | Chinese medicinal composition treating duck Tembusu virus |
| CN113995788A (en) * | 2020-07-28 | 2022-02-01 | 鲁南制药集团股份有限公司 | Composition for protecting liver and preparation process thereof |
Non-Patent Citations (5)
| Title |
|---|
| 张怡 等: "中药复方辨证干预治疗ICU抗生素相关性腹泻45例临床疗效观察", 《四川中医》 * |
| 彭成 等: "《中国临床药物大辞典 中药成方制剂卷 上》", 31 August 2018, 中国医药科技出版社 * |
| 邓中甲: "《方剂学》", 31 March 2017, 中国中医药出版社 * |
| 郑钦贤: "紫金锭仙人掌外用合荆防败毒散加减内服治疗流行性腮腺炎的临床研究", 《中国优秀博硕士学位论文全文数据库(硕士)医药卫生科技辑》 * |
| 黄抗纯: "荆防败毒散在儿科上的运用", 《湖南中医杂志》 * |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN114146122A (en) * | 2020-09-08 | 2022-03-08 | 鲁南制药集团股份有限公司 | Traditional Chinese medicine composition for treating anorexia |
| CN114272295A (en) * | 2020-09-27 | 2022-04-05 | 鲁南制药集团股份有限公司 | Traditional Chinese medicine composition for treating diabetic acromelic gangrene |
| CN114272295B (en) * | 2020-09-27 | 2023-11-24 | 鲁南制药集团股份有限公司 | Traditional Chinese medicine composition for treating diabetic acromelic gangrene |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN109674958B (en) | Traditional Chinese medicine composition with effect of reducing uric acid and preparation method and application thereof | |
| CN108888670B (en) | Colon targeting capsule for treating ulcerative colitis and preparation process thereof | |
| CN102641395A (en) | Medicament composite for treating constipation as well as preparation method and application of medicament composite | |
| CN114073731A (en) | A Chinese medicinal composition for treating abdominal pain and diarrhea | |
| CN114470114B (en) | Application of Mailuoshutong preparation in preparation of medicine for treating constipation | |
| CN111388587A (en) | Traditional Chinese medicine composition for preparing medicine for treating functional dyspepsia | |
| CN103120732B (en) | Chinese medicinal composition for treating jaundice and preparation method thereof | |
| CN104324291A (en) | Traditional Chinese medicine preparation for treating large intestine damp-heat type hemafecia and preparation method of traditional Chinese medicine preparation | |
| CN101972405B (en) | Astragalus mongholicus and perfume ginseng capsule, preparation method and application thereof | |
| CN100579564C (en) | Medicine for curing gout and its preparing method | |
| CN114272295B (en) | Traditional Chinese medicine composition for treating diabetic acromelic gangrene | |
| CN101693084B (en) | Medical composition for treating epigastric pain yin deficiency syndrome and preparation method thereof | |
| CN111375035A (en) | Preparation and application of enteric-coated preparation for treating cervical spondylosis | |
| CN104721256A (en) | Anwei Yang extract as well as preparation method and medical application thereof | |
| CN103405732A (en) | Traditional Chinese medicine patch for treating infant rotavirus enteritis and preparation method thereof | |
| CN110327435B (en) | Traditional Chinese medicine composition for treating ulcerative colitis and chronic proctitis and application thereof | |
| CN108143875B (en) | Traditional Chinese medicine composition for treating diabetic gastroparesis and preparation method thereof | |
| CN113116976A (en) | Application of traditional Chinese medicine composition in preparation of medicine for preventing or treating digestive internal diseases | |
| CN114712478A (en) | Traditional Chinese medicine composition and preparation for treating intestinal diseases and preparation method thereof | |
| CN112089783B (en) | Application of traditional Chinese medicine composition in preparation of medicine for preventing or/and treating obesity | |
| CN100457169C (en) | Medicine for treating chronic colitis and its preparing process | |
| CN108815448A (en) | A kind of Chinese herbal granules for treating chronic colitis | |
| CN108704036A (en) | A kind of Chinese traditional compound medicine and preparation method thereof for treating gout | |
| CN108379379A (en) | Chinese medicine composition for acute stage of gout | |
| CN108888731B (en) | Pharmaceutical composition for relieving cough and reducing sputum |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination |